Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy. Issue 5 (21st March 2023)

• Record Type: Journal Article
• Authors: Zahir, Hamim; Yin, Ophelia; Hsu, Ching; Wagner, Andrew J.; Jiang, Jason; Wang, Xiaoning; Greenberg, Jon; Shuster, Dale E.; Kakkar, Tarundeep; LaCreta, Frank
• Is Part Of: Clinical pharmacology in drug development. Volume 12:Issue 5(2023)
• Page Start: 475
• Page End: 483
• Publication Date: 2023-03-21
• Subjects: pexidartinib -- tenosynovial giant cell tumor -- TGCT -- bioequivalence -- pharmacokinetics -- dosing -- safety; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.1240
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The original dosing regimen is 400 mg of pexidartinib (2 × 200‐mg capsules) twice daily, administered on an empty stomach at least 1 hour before or 2 hours after a meal or snack. Because pexidartinib is likely to be taken over an extended period of time, the ability to take pexidartinib with a meal would simplify timing of administration and potentially improve compliance. Since administering 400 mg of pexidartinib with a low‐fat meal increases exposure by ≈60% relative to the fasted state, administering 250 mg of pexidartinib with a low‐fat meal (low‐fat meal dosing regimen) was predicted to achieve an exposure similar to 400 mg administered during a fasted state (original dosing regimen). Based on clinical trial simulations with two one‐sided t‐tests and bootstrapping (ie, resampling) analyses, a bioequivalence study (n = 24) would have >90% power to conclude that the original dosing regimen (400 mg fasted twice daily) and the low‐fat meal dosing regimen (250 mg with a low‐fat meal twice daily) are bioequivalent. This report provides the outcome of the implementation of the model‐informed drug development strategy to recommend and justify a low‐fat meal dosing regimen for pexidartinib that has the potential to improve patient compliance while maintaining drug exposure.